Logo

    oncogenes

    Explore " oncogenes" with insightful episodes like "Oncogenes in relation to immune responses", "Ep. 490 – Global Insights on Avian Flu: Are Waterfowl Hunters at Higher Risk?", "Normal and Malignant Stem Cells: New Opportunities and New Complexities with Connie Eaves - Breaking News in Stem Cells", "Normal and Malignant Stem Cells: New Opportunities and New Complexities with Connie Eaves - Breaking News in Stem Cells" and "Improving Survival In Oncogene Driven Lung Cancer" from podcasts like ""Immuno Oncology Talks", "Ducks Unlimited Podcast", "Stem Cell Channel (Audio)", "Stem Cell Channel (Video)" and "TOGA Podcast"" and more!

    Episodes (7)

    Oncogenes in relation to immune responses

    Oncogenes in relation to immune responses

    In our tenth episode of the “Immuno Oncology Talks”,  we will discuss oncogenes in relation to immune responses with our guest, Professor Juha Klefström, from the Finnish Cancer Institute at the University of Helsinki, Finland. Professor Klefström is an expert in breast cancer biology and immuno-oncology, leading a research group focusing on oncogenes like Myc, in relation to the immune system and the tumour immune micro environment. 

    For more information please visit :
    Sanofi Immuno Oncology Talks website


    MAT-BE-2400162 (ver.1 ) 02 2024 


    Ep. 490 – Global Insights on Avian Flu: Are Waterfowl Hunters at Higher Risk?

    Ep. 490 – Global Insights on Avian Flu: Are Waterfowl Hunters at Higher Risk?

    Dr. Richard Webby, faculty member at St Jude Children’s Research Hospital and global expert on influenza viruses, joins Drs. Mike Brasher, Karen Waldrop, and DU staff for a look back on the 2022 Avian Flu outbreak. In this science-heavy episode we ask where it came from, is it here to stay, and what can we expect going forward? We also learn why it is showing up in mammals and what this means for our pets. Also, will mutations increase the human health risk and are waterfowl hunters at higher risk?

    www.ducks.org/DUPodcast

    Improving Survival In Oncogene Driven Lung Cancer

    Improving Survival In Oncogene Driven Lung Cancer

    Join us for a conversation with internationally recognized Medical Oncologists and researchers, Professor Ben Solomon & Associate Professor Tom John as they discuss the increased survival benefits for patients with oncogene driven lung cancer and how novel treatments are contributing.

    Oncogenes discussed include EGFR & osimertinib; ALK & brigatinib, alectinib, lorlatinib; ROS1 & crizotinib, entrectinib; KRAS & sotorasib; G12C; Exon20 insertions & poziotinib, amivantamab, RET & selpercatinib, pralcetinib. Also discussed – the importance of the move beyond single gene testing to panels and NGS is important to maximise turn-around times and the efficient utilization of clinical samples.

    Journal Club: Architecting an Aggressive Cancer

    Journal Club: Architecting an Aggressive Cancer

    Mechanical forces and architecture may not sound very "bio", but they are key tools of epidermal stem cells.  These stem cells essentially engineer their environment by producing both the cells above them (the skin cells) and the extracellular matrix mesh (the basement membrane) that they sit on. In this episode we explore whether, when these stem cells acquire oncogenic mutations (the ones that cause cancer), do they now architect in a different way, and does this influence the development of cancer?

    Host Lauren Richardson and Professor Elaine Fuchs of Rockefeller University discuss her lab's recent Nature article "Mechanics of a multilayer epithelium instruct tumour architecture and function". The article investigates the differences in mechanical forces and tissue architecture in two distinct types of skin cancer: one that tends to be begin and non-invasive and one that tends to be aggressive and metastatic. The conversation covers how computational modeling played a critical role in uncovering new sources of forces and how changes in architecture influence invasive properties.

    ಸ್ತನ ಕ್ಯಾನ್ಸರನ್ನು ನಿಲ್ಲಿಸೋಣ! We Can Fight Breast Cancer.

    ಸ್ತನ ಕ್ಯಾನ್ಸರನ್ನು ನಿಲ್ಲಿಸೋಣ! We Can Fight Breast Cancer.

    October is Breast Cancer Awareness month, worldwide. Geetha Manjunath joins host Pavan Srinath to share how breast cancer is an easily treatable illness in 2020 if caught early.

    Over 80,000 women in India still die annually from breast cancer, largely from late detection of cancer. Geetha discusses why breast cancer is so frequent, what factors can lead to a higher risk of cancer, how it can be detected early through regular screening, and how it can be managed.

    Dr Geetha Manjunath is the Founder, CEO, and CTO of NIRAMAI Health Analytix. With a background in computer science, data analytics, and machine learning, she has been working for the past 6 years in healthcare and diagnostics. Niramai has innovated on a novel, safe method for detecting early-stage breast cancer which avoids the use of X-rays as used in mammograms. Visit www.niramai.com and www.niramai.org for more information. ಬನ್ನಿ ಕೇಳಿ!

    ಫಾಲೋ ಮಾಡಿ. Follow the Thalé-Haraté Kannada Podcast @haratepod. Facebook: facebook.com/HaratePod/ , Twitter: twitter.com/HaratePod/ and Instagram: instagram.com/haratepod/

    ಈಮೇಲ್ ಕಳಿಸಿ, send us an email at haratepod@gmail.com and tell us what you think of the show. The Thale-Harate Kannada Podcast is made possible thanks to the support of The Takshashila Institution and IPSMF, the Independent Public-Spirited Media Foundation.

    See omnystudio.com/listener for privacy information.

    Logo

    © 2024 Podcastworld. All rights reserved

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io